错配修复基因MSH3rs26279、MSH5rs2075789、MLH3rs175080和MSH6rs1042821对肝细胞癌发病的预测作用

刘英; 吴颖丽; 刘晓刚; 刘春梅; 王媛媛; 张晓琳; 刘殿武

doi:10.16462/j.cnki.zhjbkz.2016.11.006

错配修复基因MSH3rs26279、MSH5rs2075789、MLH3rs175080和MSH6rs1042821对肝细胞癌发病的预测作用

doi: 10.16462/j.cnki.zhjbkz.2016.11.006

1. 河北省唐山市工人医院医务部, 河北唐山 063000;
2. 河北医科大学公共卫生学院流行病与统计学教研室, 河北石家庄 050017;
3. 河北医科大学第三医院肾内科, 河北石家庄 050051

基金项目:

河北省医学科学研究重点课题计划（ZL20140008）；河北省科技计划项目（13277732D）

详细信息

作者简介:
刘英(1975-),女,河北唐山人,副主任护师,博士。主要研究方向:临床流行病学。

中图分类号: R181.32;R181.26
计量
- 文章访问数: 249
- HTML全文浏览量: 56
- PDF下载量: 31
- 被引次数: 0
出版历程
- 收稿日期: 2016-04-25
- 修回日期: 2016-09-08

Prediction on the relationship between mismatch repair MSH3rs26279,MSH5rs2075789,MLH3rs175080,MSH6rs1042821 and hepatocellular carcinoma

1. Medical Department, TangShan Worker's Hospital, TangShan 063000, China;
2. Department of Epidemiology and Statistics, Hebei Medical University, Shi Jiazhuang 050017, China;
3. Department of Nephrology, the Third Hospital of Hebei Medical University, Shi Jiazhuang 050051, China

摘要

摘要: 目的探讨错配修复基因（mismatch repair，MMR）对肝细胞癌（hepatocellular carcinoma，HCC）发病风险的预测作用。方法采用以医院为基础的病例对照研究方法，将HCC患者组做病例组，良性肝肿瘤患者为对照组。收集入院时间为2012年10月~2014年5月就诊和治疗的226例肝细胞癌和308例良性肝肿瘤患者的临床病理资料、组织DNA。应用“美国应用生物公司”开发的SNaPshot技术，也称小测序法，对MSH3rs26279、MSH5rs1150793、rs2075789、MSH6rs1042821、MLH3rs175080、PMS1rs5742933和PMS2rs1059060，6个基因的7个位点进行基因分型。运用非条件Logistic回归分析MSH3、MSH5、MSH6、MLH3、PMS1和PMS2基因型在两组中分布频率的差异。结果 MSH3rs26279AG和GG基因型；MSH5rs2075789AA基因型；MLH3rs175080AA基因型均增加了肝细胞癌的发病风险（均有P<0.05）；MSH6rs1042821CT基因型（OR=0.716，95%CI：0.497～0.942）降低了肝细胞的发病风险；尚未发现MSH5rs1150793、PMS1rs5742933和PMS2rs1059060位点与肝细胞癌的发病关联（均有P>0.05）。结论错配修复基因MSH3、MSH5MLH3和MSH6可能与肝细胞癌的发病有关联，其rs26279、rs2075789、rs1042821位点的多态性对肝细胞癌的发病有预测作用。
- 错配修复 /
- 肝细胞癌 /
- 预测
Abstract: Objective To study the prediction effect of Mismatch repair gene and the risk of hepatocellular carcinoma. Methods A hospital-based case-control study on hepatocellular carcinoma was conducted.226 HCC and benign liver tumor patients were recruited as case group and control group, respectively. Their pathological data and tissue DNA were collected from October 2012 to May 2014. Applied Biotechnology,also know as technology developed SNaPshot, a small sequencing were used for genotyping MSH3rs26279,MSH5rs1150793, rs2075789, MSH6rs1042821, MLH3rs175080, PMS1rs5742933 and PMS2rs1059060. Unconditional Logistic regression were used to analyze MSH3, MSH5, MSH6, MLH3, PMS1 and PMS2 genotype frequencies in both groups. Resuts MSH3rs26279AG and GG genotype(OR values were 1.587 and 2.852,95% CI were 1.206-2.689 and 1.863-5.734), MSH5rs2075789AA genotype(OR=10.123, 95% CI:1.526-69.258), MLH3rs175080AA genotype (OR=3.867,95% CI:1.143-9.589) had increased risk of hepatocellular carcinoma; MSH6rs1042821CT genotype(OR=0.716,95% CI:0.497-0.942) had lower risk of hepatocellular carcinoma; no collection of MSH5rs1150793, PMS1rs5742933 and PMS2rs1059060 with hepatocellular carcinoma(P>0.05) were found. Conclusions Mismatch repair genes MSH3,MSH5,MLH3 and MSH6 might associated with the risk of hepatocellular carcinoma,which the polymorphism of rs26279, rs2075789, rs175080 and rs1042821 are risk factors of hepatocellular carcinoma.
- Mismatch repair /
- Hepatocellular carcinoma /
- Prediction